Skip to main content
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc — Investor Relations & Filings

Ticker · XFOR ISIN · US0428731097 LEI · 549300R0UFVPXWP86U94 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2018-08-10 Major Shareholding Noti…
Country US United States of America
Listing US XFOR

About X4 Pharmaceuticals, Inc

https://www.x4pharma.com/

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases of the immune system. The company focuses on diseases resulting from the dysfunction of the CXCR4 pathway, a key signaling pathway for immune cell trafficking. Its lead product, XOLREMDI™ (mavorixafor), is an oral, selective antagonist of the CXCR4 receptor. It is approved for use in patients aged 12 and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) to increase the number of circulating neutrophils and lymphocytes. The company's pipeline includes further investigation of mavorixafor for other chronic neutropenic disorders.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2018
Major Shareholding Notification
2018-08-10 English
FORM 3 SUBMISSION
Director's Dealing
2018-07-17 English
FORM 3 SUBMISSION
Director's Dealing
2018-07-17 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it reports the completion of an interim analysis of a clinical trial and includes a press release as an exhibit. There are no financial statements or detailed financial data presented, nor is this an annual or quarterly report. The document is short (2974 characters) and primarily serves as an announcement of an event and a press release filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2018-06-28 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the company's entry into a material definitive agreement, specifically a lease agreement for office space. There are no financial statements or detailed financial performance data included. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing announcing a significant corporate event. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is 5758 characters, which is consistent with a typical 8-K filing. Confidence is high because the document explicitly states it is a Form 8-K and the content matches the description of a regulatory announcement.
2018-06-12 English
FORM 4 SUBMISSION
Director's Dealing
2018-06-07 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.